Skip to main content
. 2020 Apr 4;18:100560. doi: 10.1016/j.conctc.2020.100560

Table 2.

Schedule of study measures.

Assessment Baseline
In-person
Every week
In-person or phone
Every month
In-person
End-of-program
In-person
12-week follow-up Phone
Primary outcome
 PAI-1 X X
Secondary outcomes
 Blood pressure and heart rate X X X
 BMI and weight X X X X
 Body composition X X X
 Cardiopulmonary fitness X X
 Cholesterol X X
 Dietary composition X X X X
 Glycemic controla X X
 HRQOL X X X
 Inflammationb X X
 Liver enzymes X X
 Liver histologyc X X (optional)
 Markers of hemostasisd X X
 MRI-PDFF/liver volume X X
 Microbiome X X
 NASH biomarkerse X X
 NASH Clinical Decision Aidsf X X
 PNPLA3 genotype X
 PNPLA3 expression X X
Covariates
 Activity level X X X X X
 Medical/surgical/social history X X X
 NASH and other medications X X X
 Sociodemographics X
 Sleep quality X X X X

BMI = body mass index; HRQOL = health-related quality of life; MRI-PDFF = magnetic resonance imaging proton density fat fractionation; PNPLA3 = Patatin like phospholipase-3.

a

Hemoglobin A1c, Insulin level, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

b

Ferritin and White blood cell count.

c

NASH Activity Score and Fibrosis assessment.

d

Antithrombin, Factor VII, ADAMTS-13, D-dimer, Factor VIII, Fibrinogen, International Normalized Ratio (INR), P-selection, Platelet count, Protein S, Protein C, Thromboelastography (TEG), von Willebrand Factor.

e

Adiponectin, Cytokeratin (CK)-18.

f

NAFLD Fibrosis Score, Fibrosis-4 Index (FIB-4).